Skip to main content
. 2021 Aug 3;5(9):e10530. doi: 10.1002/jbm4.10530

Fig. 5.

Fig. 5

Anti‐TGF‐β antibody 1D11 induces robust and durable dose‐frequency–related increases in femoral bone trabecular parameters in mice with osteogenesis imperfecta (OI) measured by μCT imaging. (A) Bone volume, (B) trabecular separation, (C) trabecular number, and (D) trabecular thickness measured in femoral metaphysis of WT and OI mice. μCT femur n = 8, 5, 5, 8, 8, and 8 for groups 1–6, respectively. Mean ± SD and asterisk(s) denote statistically significant difference compared with OI 13C4, 10 mg/kg ip. a0.01 < p < 0.05. b0.001 < p < 0.01. c0.0001 < p < 0.001. d p < 0.0001. Dosing regimen: 3 × wk = three weekly doses; 1 × wk = 1 weekly dose; 1 × 2 wk = one dose every other week; 1 × 4 wk = one dose every 4 weeks; all doses 5 mg/kg ip. BV/TV = bone volume fraction; Tb.N = trabecular number; Tb.Sp = trabecular spacing; Tb.Th = trabecular thickness.